COMP <GO>
NPCE vs ABBV // EV/EBITDA & P/E VALUATION
Neuropace Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NPCE 2
— ABBV 9
■ METRIC PARITY
LAST: $13.01 (+0.62%) • MKT CAP: $446.6M
valuation
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPCE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPCE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | 70.20% | +7.00 | NPCE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.00% | 29.00% | -52.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.54% | 3.47% | -6.01 | ABBV | /fcf-yield <GO> |
| Operating Margin | -16.30% | 24.60% | -40.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 6.90% | -28.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 25.10% | 8.60% | +16.50 | NPCE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.3 | 65.1 | -25.81 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $446.6M | $513.86B | -$513.41B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPCE REV | ABBV REV | NPCE GROSS % | ABBV GROSS % | NPCE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $100.0M | $61.16B | 77.2% | 70.2% | -$11.3M | $17.82B |
| FY 2024 | $79.9M | $56.33B | 73.9% | 70.0% | -$18.3M | $17.83B |
| FY 2023 | $65.4M | $54.32B | — | — | -$19.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPCE // BETA —
ABBV // BETA 1.15